PA
MRVI icon

Parallel Advisors’s Maravai LifeSciences MRVI Stock Holding History

Parallel Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$761 Sell
269
-3,516
-93% -$11.9K ﹤0.01% 3584
2025
Q4 		$12.3K Hold
3,785
– – ﹤0.01% 2520
2025
Q3 		$10.9K Buy
+3,785
New +$9.66K ﹤0.01% 2507
2025
Q2 		– Sell
-787
Closed -$1.74K – 3655
2025
Q1 		$1.74K Sell
787
-213
-21% -$842 ﹤0.01% 3011
2024
Q4 		$5.45K Sell
1,000
-432
-30% -$2.78K ﹤0.01% 2610
2024
Q3 		$11.9K Sell
1,432
-89
-6% -$769 ﹤0.01% 2332
2024
Q2 		$10.9K Buy
1,521
+71
+5% +$613 ﹤0.01% 2280
2024
Q1 		$12.6K Sell
1,450
-560
-28% -$3.79K ﹤0.01% 2208
2023
Q4 		$13.2K Buy
2,010
+902
+81% +$5.83K ﹤0.01% 2169
2023
Q3 		$11.1K Buy
1,108
+978
+752% +$10.7K ﹤0.01% 2144
2023
Q2 		$1.62K Sell
130
-907
-87% -$12.2K ﹤0.01% 2813
2023
Q1 		$14.5K Buy
1,037
+163
+19% +$2.34K ﹤0.01% 1974
2022
Q4 		$12.5K Buy
874
+727
+495% +$11.4K ﹤0.01% 1942
2022
Q3 		$4K Buy
+147
New +$3.69K ﹤0.01% 2394

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parallel Advisors's MRVI Position: Q1 2026 in Review

Parallel Advisors reduced its Maravai LifeSciences (MRVI) stake by 93% in Q1 2026, selling an estimated $11.9K and leaving 269 shares worth $761. The position accounts for ﹤0.01% of the portfolio, ranked #3584.

Parallel Advisors first reported a position in MRVI in Q3 2022 and has held it in 14 quarters since. The position peaked at $14.5K in Q1 2023. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Parallel Advisors held 269 shares of Maravai LifeSciences worth $761 as of Q1 2026.
  • Parallel Advisors sold 3,516 Maravai LifeSciences shares in Q1 2026, an estimated $11.9K.
  • Maravai LifeSciences made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3584 holding.
  • Parallel Advisors first reported a position in Maravai LifeSciences in Q3 2022 and has held it in 14 quarters since.
  • Parallel Advisors's Maravai LifeSciences position peaked at $14.5K in Q1 2023.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.